BioStock: Multiple near-term milestones for ExpreS2ion Biotech

With an upcoming phase III readout and ongoing toxicology studies it is safe to say that ExpreS2ion Biotech has an interesting year ahead. On top of that, new partnerships are formed to further strengthen the value of the portfolio. The company now seeks to raise 102 Mkr in a rights issue for the financing of the ongoing studies and business development.

Read the full article at biostock.se:

https://www.biostock.se/2023/03/multiple-near-term-milestones-for-expres2ion-biotech/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

The invitation to persons concerned to subscribe for units in ExpreS2ion Biotechnologies will only take place through the prospectus published on 27 March 2023. The prospectus has been approved and registered by the Financial Supervisory Authority and published on https://expres2ionbio.com/.